Bayer, Janssen, M-S, AZ, Sanofi, Lundbeck, UCB fuel €170M EU-wide screening honeypot
This article was originally published in Scrip
Seven pharmaceutical companies are taking part in a new European public-private drug discovery collaboration under which academia and industry will assemble a pool of hundreds of thousands of compounds as a way of attracting researchers with novel screening approaches and targets. A key part of the move is to develop compounds from academia that are designed to address "difficult and so far intractable" targets.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.